T. Rowe Price Associates
JNCE

T. Rowe Price Associates’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

T. Rowe Price Associates’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-80,336
Closed -$149K – 3026
2023
Q1 		$149K Hold
80,336
– – ﹤0.01% 2598
2022
Q4 		$89K Buy
80,336
+41,000
+104% +$58.4K ﹤0.01% 2739
2022
Q3 		$93K Buy
39,336
+19,718
+101% +$69.8K ﹤0.01% 2744
2022
Q2 		$59K Sell
19,618
-44,691
-69% -$217K ﹤0.01% 2841
2022
Q1 		$437K Buy
64,309
+54,115
+531% +$386K ﹤0.01% 2396
2021
Q4 		$85K Sell
10,194
-191,300
-95% -$1.58M ﹤0.01% 2891
2021
Q3 		$1.5M Buy
201,494
+15,636
+8% +$96.9K ﹤0.01% 1853
2021
Q2 		$1.26M Buy
185,858
+45,232
+32% +$376K ﹤0.01% 1963
2021
Q1 		$1.44M Buy
140,626
+35,630
+34% +$390K ﹤0.01% 1864
2020
Q4 		$735K Buy
+104,996
New +$817K ﹤0.01% 2080

Other funds holding JNCE

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

T. Rowe Price Associates's JNCE Position: Q2 2023 in Review

T. Rowe Price Associates sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 80,336 shares — an estimated $149K sold.

T. Rowe Price Associates first reported a position in JNCE in Q4 2020 and held it in 10 quarters. The position peaked at $1.5M in Q3 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • T. Rowe Price Associates reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 80,336 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $149K.
  • T. Rowe Price Associates first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
  • T. Rowe Price Associates's Jounce Therapeutics, Inc. Common Stock position peaked at $1.5M in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.